The Clinical Protocol Scientific Review and Monitoring System (CPSRMS) of the Robert H. Lurie Comprehensive Cancer Center (Cancer Center) is composed of several key committees including the Clinical Protocol Scientific Review and Monitoring Committee (CPSRMC), Data Monitoring Committee (DMC), and the Audit Committee. The CPSRMC is charged with the responsibility of evaluating all new and ongoing clinical research protocols for scientific merit and institutional priority. This is required for all studies that have not received review and approval from an NCI-approved external peer review group. The CPSRMC is a multidisciplinary committee that consists of a core group providing the necessary expertise in the principal disciplines of clinical oncology with additional representation from Biostatistics, Laboratory Science, Pharmacy, and Nursing. The CPSRMC is directly responsible for: 1) reviewing new clinical trials to ensure that they are scientifically sound, 2) ensuring study priority has been assigned appropriately by the study Principal Investigator, 3) confirming that the clinical trials are relevant to the goals of the Cancer Center, 4) reviewing for adequacy of data and safety monitoring plans for each new protocol, 5) reviewing and approving all letters of intent prior to development of a local investigator-initiated clinical trial, and 6) reviewing and approving protocol amendments prior to IRB submission. The CPSRMS delegates responsibility for data and safety monitoring of clinical trials to the DMC and Audit Committee, whose activities are described in more detail in section 12.0, Data and Safety Monitoring.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Moinpour, Carol M; Donaldson, Gary W; Davis, Kimberly M et al. (2017) The challenge of measuring intra-individual change in fatigue during cancer treatment. Qual Life Res 26:259-271
Lamar, Tyra; Vanoye, Carlos G; Calhoun, Jeffrey et al. (2017) SCN3A deficiency associated with increased seizure susceptibility. Neurobiol Dis 102:38-48
Yu, Dou; Khan, Omar F; SuvĂ , Mario L et al. (2017) Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci U S A 114:E6147-E6156
Mohr, David C; Tomasino, Kathryn Noth; Lattie, Emily G et al. (2017) IntelliCare: An Eclectic, Skills-Based App Suite for the Treatment of Depression and Anxiety. J Med Internet Res 19:e10
Apple, Alexandra C; Ryals, Anthony J; Alpert, Kathryn I et al. (2017) Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. Neuroimage Clin 14:685-691
Lampe, Johanna W; Huang, Ying; Neuhouser, Marian L et al. (2017) Dietary biomarker evaluation in a controlled feeding study in women from the Women's Health Initiative cohort. Am J Clin Nutr 105:466-475
Ichikawa, Yuichi; Connelly, Caitlin F; Appleboim, Alon et al. (2017) A synthetic biology approach to probing nucleosome symmetry. Elife 6:
Zhou, Qiyuan; Dai, Jingbo; Chen, Tianji et al. (2017) Downregulation of PKC?/Pard3/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion. Cell Signal 38:49-59
Park, Jong Kook; Peng, Han; Yang, Wending et al. (2017) miR-184 exhibits angiostatic properties via regulation of Akt and VEGF signaling pathways. FASEB J 31:256-265
Raji, Idris; Yadudu, Fatima; Janeira, Emily et al. (2017) Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase. Bioorg Med Chem 25:1202-1218

Showing the most recent 10 out of 1878 publications